Clinical Trials
2 trialsNCT04915248 2026-06-02
FIL_DALYA
Fondazione Italiana Linfomi - ETS
Phase 2 Recruiting
NCT02927925 2021-01-14
A Study to Assess the Clinical Efficacy and Safety of Daratumumab in Participants With Relapsed or Refractory Natural Killer/T-Cell Lymphoma (NKTCL), Nasal Type
Janssen Research & Development, LLC
Phase 2 Completed